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Abstract 
 
Background: Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro. 
Methods: An international, randomized, double-blind, double-dummy, active-controlled trial was 
conducted to evaluate the efficacy and safety of COBI versus ritonavir (RTV) as a 
pharmacoenhancer of atazanavir (ATV) in combination with emtricitabine (FTC)/ tenofovir 
disoproxil fumarate (TDF) in treatment-naïve patients. Primary endpoint was HIV-1 RNA < 50 
copies/mL at Week 48 by FDA snapshot algorithm; non-inferiority margin was 12%. 
Results: A total of 692 patients were randomized and received study drug (344 COBI vs 348 
RTV group). At Week 48, virologic success was achieved in 85% (COBI) and 87% (RTV) 
(difference: −2.2%; 95% CI: −7.4 to 3.0); among patients with baseline HIV-1 RNA >100,000 
copies/mL, rates were similar (86% vs 86%). Similar percentages of patients in both groups had 
serious adverse events (10% vs 7%) and adverse events leading to study drug discontinuation 
(7% vs 7%). Median increases in serum creatinine were 0.13 and 0.09 mg/dL, respectively.  
Conclusions: COBI was non-inferior to RTV in combination with ATV plus FTC/TDF at Week 
48. Both regimens achieved high rates of virologic success. Safety and tolerability profiles of the 
two regimens were comparable. Once-daily COBI is a safe and effective pharmacoenhancer of 
the protease inhibitor ATV. 
Clinical Trials Registration: NCT01108510. 
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Introduction 
The use of a pharmacoenhancer, primarily low dose (100-400 mg/day) ritonavir (RTV), to boost 
protease inhibitors (PIs)  has had a significant impact on the treatment of HIV infection by 
improving the pharmacokinetic profiles of the boosted drug, resulting in durable efficacy, high 
barrier to resistance, reduced pill burden and dosing frequency [1].   
Cobicistat (COBI) is a novel pharmacoenhancer that was developed to “boost” the plasma levels 
of elvitegravir (EVG) or PIs. Preclinical studies demonstrated that COBI is more selective than 
RTV in inhibiting CYP3A with a low potential for induction, which may lead to fewer or more 
predictable drug–drug interactions, and without antiretoriviral activity in vitro, which eliminates 
any potential of conferring PI resistance when used as a pharmacoenhancer of a non-PI, such as 
EVG [2].  
In a phase 2 study of treatment-naïve patients, COBI was well-tolerated and demonstrated 
similar efficacy to RTV as a pharmacoenhancer for atazanavir (ATV) in combination with 
emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) [3]. ATV was selected as the PI to be 
boosted by COBI, as it is the preferred PI for naïve patients [4, 5]. COBI was also studied as a 
component of a single tablet regimen (STR), Stribild (EVG/COBI/FTC/TDF), in two large 
randomized controlled trials that demonstrated its efficacy and safety [6, 7]. 
In this paper, we present the result of a phase 3 study in treatment-naïve patients comparing 
COBI versus RTV as a pharmacoenhancer for ATV in combination with FTC/TDF.  
 
Methods 
Patients: Study GS-US-216-0114 (ClinicalTrials.gov number NCT01108510) is an ongoing 
phase 3 study assessing the efficacy and safety of COBI versus RTV in combination with ATV 
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and FTC/TDF as initial HIV treatment. The study is being conducted internationally and was 
approved by institutional review boards or ethics committees at all investigative centers. All 
patients gave written informed consent. 
Patients (target n = 700) were HIV-1 infected adults at least18 years old with plasma HIV-1 
RNA ≥ 5000 copies/mL and no prior use of antiretroviral agents.  An estimated glomerular 
filtration rate (eGFR) of at least 70 mL/min and sensitivity to ATV, FTC, TDF by HIV-1 
genotype (GeneSeq™ assay, Monogram Biosciences, South San Francisco, CA, USA) were 
required at screening. Additional inclusion criteria included aspartate and alanine 
aminotransferase levels no more than five times upper limit of normal; total bilirubin no more 
than 1.5 mg/dL or a normal direct bilirubin, absolute neutrophil count at least 1,000 cells per 
mm3; platelet count at least 50,000 per mm3; hemoglobin at least 8.5 g/dL; and a negative serum 
pregnancy test (if applicable). Positive hepatitis B surface antigen or hepatitis C antibody was 
allowed. There was no screening CD4 cell count requirement; patients with new AIDS-defining 
conditions or serious infections within 30 days of screening were excluded.  
Randomization and blinding: Eligible patients were randomized 1:1 to receive either COBI or 
RTV, each administered once daily. Patients also received placebo tablets matching the 
alternative treatment; thus, investigators, patients, and study staff were blinded to the treatment 
group. A computer-generated allocation sequence using a block size of four was created by 
Bracket (San Francisco, CA, USA), and randomization was stratified by screening HIV-1 RNA 
(≤ and >100,000 copies/mL). Investigators randomized patients to one of the two treatment arms 
by phone or internet using an interactive system (provided and managed by Bracket). 
Procedures: Study visits occurred at Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48. Patients were to 
continue blinded treatment assignments with visits every 12 weeks until Week 192.  Safety was 
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assessed by laboratory tests, physical examinations, and adverse events. Laboratory analyses 
included hematology, serum chemistry, and urinalysis (Covance Laboratories, Indianapolis, IN, 
USA) and HIV-1 RNA (Amplicor HIV-1 Monitor Test [v1.5]; Roche Diagnostics, Rotkreuz, 
Switzerland). The HIV-1 genotype (reverse transcriptase and protease only) was analyzed at 
screening using the GeneSeq™ assay.  In patients taking study drugs with confirmed virologic 
rebound of HIV-1 RNA ≥ 400 copies/mL or who did not achieve < 400 copies/mL at or after 
Week 8, protease and reverse transcriptase genotyping and phenotyping assays were done with 
PhenoSense GT, PhenoSense Integrase, and GeneSeq Integrase (Monogram Biosciences). 
Preliminary results by treatment group were reviewed by an independent data monitoring 
committee (IDMC) when half of patients completed Week 12 and when all patients completed 
Weeks 24 and 48 of follow-up.   
Statistical analysis: The primary analysis included all clinical, laboratory, and virologic data 
available after the last patient had completed the Week 48 study visit or prematurely 
discontinued study drug. The primary endpoint was the proportion of patients with virologic 
suppression (HIV-1 RNA <50 copies/mL) at Week 48 per the US Food and Drug Administration 
(FDA)-defined snapshot analysis; the intention-to-treat (ITT) population was used to assess 
treatment non-inferiority of COBI compared with RTV using a conventional 95% CI approach 
with a prespecified non-inferiority margin of 12%. In the FDA snapshot analysis, patients with 
HIV-1 RNA < 50 copies/mL between days 309 to 378 (Week 48 window) were classified as 
successes. Patients with HIV-1 RNA >= 50 copies/mL at Week 48 analysis window or no HIV-1 
RNA data in the Week 48 analysis window due to missing data or discontinuation of study drug 
were considered non-successes. The baseline HIV-1 RNA stratum (≤100,000 copies/mL or 
>100,000 copies/mL)-weighted difference in the response rate and its 95% CI were calculated 
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based on stratum-adjusted Mantel-Haenszel proportion. For each interim analysis performed, an 
alpha of 0.001 was spent. Therefore, the significance level for the two-sided test for virologic 
response at Week 48 according to the FDA snapshot algorithm, for ITT and per-protocol (PP) 
populations, was 0.048, corresponding to a 95.2% CI. A sample size of 700 patients provided at 
least 95% power to establish non-inferiority with respect to the percentage of patients achieving 
virologic success at Week 48, as defined by the FDA snapshot analysis, between the two 
treatment groups. This assumes response rates of 79.5% in both treatment groups [8], a non-
inferiority margin of 12%, and using a significance level of the test at a one-sided, 0.025 level. 
Calculations were made using nQuery Advisor, Version 6.0 (Statistical Solutions, Saugus, MA). 
A per protocol snapshot analysis was conducted that included all patients who (1) were 
randomized into the study, (2) received at least one dose of study drug, and (3) did not meet any 
pre-specified criteria, such as discontinuation of study drug for reasons other than lack of 
efficacy with no Week 48 HIV-1 RNA data. Supporting analyses included subgroup analyses to 
assess treatment differences between specified subgroups (i.e., age, sex, race, baseline HIV-1 
RNA, baseline CD4 cell count, and study drug adherence as assessed by pill counts).  Additional 
efficacy endpoints at Week 48 were the achievement and maintenance of HIV-1 RNA < 50 
copies/mL by the FDA-defined time to loss of virologic response (TLOVR) algorithm [9], the 
percentage of patients with HIV-1 RNA < 50 copies/mL using missing = failure and missing = 
excluded methods, change from baseline in HIV-1 RNA (log10 copies/mL), and change from 
baseline in CD4 cell count.  
The safety analysis set included all randomized patients who received at least one dose of study 
drug. All safety data collected on or after the date study drug was first administered and up to 30 
days after the last dose of study drug (if patients discontinued study drug) were summarized 
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descriptively by treatment group. Safety assessments included adverse events, concomitant 
medications, laboratory tests (chemistry, hematology, urinalysis, and urine pregnancy testing), 
12-lead electrocardiograms (ECGs), height, and weight. Adverse events were coded using the 
Medical Dictionary for Regulatory Activities (MedDRA version 14.0). eGFR was calculated 
using the Cockcroft-Gault method. The Fishers Exact and Wilcoxon rank sum tests were used to 
compare treatment differences in adverse event and continuous laboratory results, respectively 
(SAS Version 9.2, SAS Institute, Cary, NC, USA). 
 
Results 
Patient screening began in April 2010, and by November 2010, 698 patients had been 
randomized. Of these, 692 received study medication, 344 in the COBI group and 348 in the 
RTV group (Figure 1). Demographic and general baseline characteristics were similar between 
the two treatment groups (Table 1). Overall, 39.7% of patients had baseline HIV-1 RNA > 
100,000 copies/mL. There was no difference in baseline eGFR between the treatment groups. 
Study drug discontinuation rates and reasons for discontinuation were similar between treatment 
groups. The last patient’s Week 48 visit was completed in November 2011.  At interim reviews 
and Week 48, the IDMC recommended that the study continue as planned. 
The study met its primary objective of non-inferiority of COBI versus RTV in combination with 
ATV and FTC/TDF. In the COBI group, 293 (85.2%) of 344 patients had HIV-1 RNA < 50 
copies/mL at Week 48 compared with 304 (87.4%) of 348 patients in the RTV group by the FDA 
snapshot ITT analysis (observed difference−2.2% [95% CI: −7.4% to 3.0%]). Other efficacy 
endpoints also indicated that virologic responses to COBI and RTV were similar (Supplemental 
Table 1), including the FDA-defined TLOVR analysis, which showed comparable virologic 
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suppression rates (82.8% [285 of 344] and 85.3% [297 of 348], respectively (observed difference 
−2.6% [95% CI: −8.1% to 2.8%]). The proportion of patients with HIV-1 RNA < 50 copies/mL 
by missing = failure, ITT analysis was also comparable between the two groups (Figure 2).  
Responses to COBI were comparable to RTV across patient subgroups at Week 48 
(Supplemental Figure 1), including patients with HIV-1 RNA >100,000 copies/mL at baseline: 
COBI 86.4% vs RTV 86.0%. Mean increases in CD4 cell count at most time points were similar 
in the two groups (+213 and +219 cells per mm3 at Week 48). 
Of the 692 randomized and treated patients, 24 (3.5%) met criteria for resistance testing, 12 of 
344 (3.5%) in the COBI group and 12 of 348 (3.4%) in the RTV group. Of the 10 patients in the 
COBI group with available data, none developed resistance mutations to PIs or TDF; two 
developed resistance mutations to FTC (M184V). Of the 12 patients in the RTV group, none 
developed resistance mutations. 
Reported adverse events are summarized in Table 3.  Most adverse events reported in each group 
were mild or moderate. No patients died during the study. The numbers of patients who 
discontinued treatment because of an adverse event were similar in the two groups (7.3% [25 
patients] in the COBI group and 7.2% [25 patients] in the RTV group, Table 4). The most 
common adverse events were related to elevated bilirubin, such as hyperbilirubinemia, jaundice, 
or scleral icterus, which occurred in a similar percentage of patients in the COBI and RTV group 
(40.7% vs 36.2%); these were also the most common adverse events leading to discontinuation 
in both groups (3.5% vs 3.2%). The rates of diarrhea and nausea did not differ between the two 
groups.  
Renal adverse events leading to treatment discontinuation were reported for 6 patients (1.7%) in 
the COBI and 5 patients (1.4%) in the RTV group. In the COBI group, 1 of the 6 patients had 
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baseline serum creatinine 0.86 mg/dL and eGFR 70.0 mL/min and discontinued due to a 
confirmed eGFR < 50 mL/min per protocol although the absolute change in serum creatinine was 
small (approximately +0.4 mg/dL); serum creatinine improved to 0.95 mg/dL after 
discontinuation of study drug. The other 5 COBI patients had laboratory findings consistent with 
proximal tubulopathy, such as hypophosphatemia, proteinuria, or normoglycemic glycosuria; 4 
of these 5 patients had follow up data available. All 4 patients experienced improvement in their 
renal laboratory values (serum creatinine, serum phosphate, urine protein, and urine glucose) 
after discontinuing the study drug. One patient had complete reversal of serum creatinine and all 
3 other abnormalities. The other 3 patients had complete reversal of hypophosphatemia, 
proteinuria, or glycosuria, while serum creatinine improved. One COBI patient had no follow up 
data after developing proximal tubulopathy in the setting of Enterobacter sepsis and acute renal 
failure (serum creatinine 5.07 mg/dL and eGFR 17 mL/min). In the RTV group, 3 of the 5 
patients had increases in serum creatinine that were not accompanied by features of proximal 
tubulopathy. In the other 2 patients who had proximal tubulopathy, serum creatinine improved 
and other markers of proximal tubulopathy completely reversed; 1 patient started on a regimen 
containing ritonavir. No patient required dialysis. A small increase in serum creatinine (median 
change at Week 48 from baseline +0.13 vs +0.09 mg/dL, P<0.001) and a corresponding decrease 
in eGFR (median change -12.9 vs -9.1 mL/min, P<0.001) was seen in both groups. Most of the 
change in serum creatinine in both groups occurred by Week 8 with little progression between 
Weeks 8 and 48 (Figure 3). 
Based on the safety profile of TDF, bone safety was assessed. Fractures occurred in 2 patients 
(0.6%) in the COBI and 4 patients (1.1%) in the RTV group; one patient in the RTV group had 
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non-traumatic spinal compression fracture, which was considered old and not acute; all other 
fractures were trauma-related. 
As expected with the use of boosted ATV, hyperbilirubinemia was the most common Grade 3 to 
4 laboratory abnormality and was more common in the COBI group (65.3% vs 56.6%). 
However, as mentioned above, rate of discontinuation due to bilirubin-related adverse events was 
low and similar in both groups. The incidence of Grade 3 to 4 liver enzyme elevation was similar 
in the two groups (AST: 2.9% vs 2.0%; ALT: 3.2% vs 2.0%). One subject from each group had 
Grade 3 to 4 liver enzyme elevations (AST or ALT) and hyperbilirubinemia along with direct 
bilirubin > 1.5 mg/dL, which suggests that the hyperbilirubinemia may not have been associated 
with ATV. The subject in the COBI group had acute hepatitis C infection, and the subject in the 
RTV group had suspected acute hepatitis B infection. 
Numerically smaller increases from baseline to Week 48 in COBI than RTV were observed for 
fasting total cholesterol (+5 vs +9 mg/dL, p=0.081) and triglycerides (+19 vs +32 mg/dL, 
p=0.063). No other differences were observed between treatment groups in safety laboratory, 
body weight, or ECG results. 
 
Discussion 
In this large, randomized, double-blinded study, COBI demonstrated high and comparable 
efficacy that was non-inferior to standard-of-care RTV as a pharmacoenhancer of ATV. The 
results were consistent across a range of endpoints, including the primary FDA-defined snapshot 
analysis, the TLOVR algorithm, and a per-protocol (as treated) analysis. In addition, the 
response in the COBI group was comparable to RTV group across all subgroups; virologic 
success rates in patients with baseline HIV-1 RNA >100,000 copies/mL were high and 
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comparable in the two treatment groups. Virologic suppression in this study (85 vs 87%) was 
similar to that seen in other recent randomized clinical trials of boosted PIs  plus FTC/TDF at 
Week 48 that reported confirmed virologic response: darunavir (DRV) + RTV 84% vs lopinavir 
(LPV)/RTV 78% in ARTEMIS (per-protocol) [10]; ATV + RTV 78% vs LPV/RTV 76% in 
CASTLE (ITT) [11].  
In phase 2 trials, COBI rapidly induced a small increase in serum creatinine with a consequent 
reduction in eGFR [3, 12, 13]. This phenomenon is due to COBI inhibition of the tubular 
secretion of creatinine, with no effect on actual GFR as measured by iohexol clearance [13]. 
RTV has also been shown to inhibit MATE-1, a renal transporter used for tubular secretion of 
creatinine [14]. Consistent with these findings, a small increase in serum creatinine was seen in 
both the COBI and RTV group in our study. The changes in serum creatinine in both groups 
were observed as early as Week 2, and appeared to stabilize by Week 8 without further increase 
up to Week 48. Some observational studies found that boosted PI regimens used with TDF may 
be associated with higher incidence of chronic kidney disease or a greater decrease in eGFR [15, 
16]. However, given the inhibitory effect of RTV on creatinine tubular secretion, studies that use 
serum creatinine or its derivatives, such as eGFR, as the primary renal outcome need to be 
interpreted with caution.  
Rates of renal discontinuation in our study (COBI 1.7 vs RTV 1.4%) were consistent with 
previous studies. In ACTG5202, 6 of 464 (1.3%) patients receiving ATV boosted by RTV plus 
FTC/TDF discontinued or reduced the dose of FTC/TDF because of changes in renal function 
[17]. Other studies of TDF-containing boosted PI regimens found similar rates of renal TDF 
discontinuation (or switch), ranging from 0 to 3% [18-26]. In our study, a small and similar 
number of patients discontinued study drug due to proximal tubulopathy (5 COBI and 2 RTV 
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patients).  This is consistent with the safety profile of TDF, which has been associated with 
proximal tubulopathy (or Fanconi syndrome) [27]. In all patients who developed proximal 
tubulopathy and had follow up data, tubular abnormalities (proteinuria, glycosuria, or 
hypophosphatemia) reversed and serum creatinine improved. The current study will continue in a 
blinded fashion to further assess the long term safety of COBI, including renal safety using 
investigator-reported adverse events and renal laboratory parameters (serum creatinine, serum 
phosphate, urine protein, urine glucose).  
The gastrointestinal tolerability of COBI was similar to that of RTV. Gastrointestinal adverse 
events, such as nausea, vomiting (7.3% vs 4.6%), or diarrhea, were similar between the two 
groups, were mostly of mild severity, and rarely led to study drug discontinuation (1 COBI 
patient for vomiting, 1 RTV patient for nausea, none for diarrhea). 
Our study does not provide data in HIV-infected patients with lower eGFRs, as an eGFR of at 
least 70 mL/min was required at entry. A study to evaluate the use of COBI as a 
pharmacoenhancer for PI (ATV or DRV) or as a component of the single tablet regimen 
EVG/COBI/FTC/TDF in patients with eGFR ranging from 50 to 90 mL/min (ClinicalTrials.gov 
number NCT01363011) is ongoing.  
Notably, the mean baseline CD4 count for patients in both treatment arms exceeded 350 
cells/mm3. This high baseline CD4 cell count reflects a trend toward initiation of HIV therapy at 
earlier stages of disease and is in line with recent HIV treatment guidelines, which recommend 
antiretroviral therapy for all individuals with HIV infection, regardless of CD4 count [4, 5]. 
The lack of antiretroviral activity of COBI is an advantage over RTV, which may lead to PI 
resistance if used as a pharmacoenhancer of a non-PI (e.g. EVG) [2]. In addition, the 
physiochemical properties of COBI, such as high intrinsic solubility and dissolution rate, make it 
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amenable to co-formulation with one or more antiretroviral agents [28]. Currently, COBI is 
being developed not only as a stand alone pharmacoenhancer, but also as a component of several 
fixed dose combination tablets which contain EVG, ATV, or DRV.  
In conclusion, COBI demonstrated high and non-inferior efficacy as a pharmacoenhancer of 
ATV compared to standard-of-care RTV. The renal safety profile of COBI is similar to that of 
other TDF-containing RTV-boosted PI regimens. COBI may become an important alternative to 
RTV as a pharmacoenhancer. 
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Table 1. Baseline characteristics 
 
COBI  
(n=344) 
RTV  
(n=348) 
Age (years), mean (SD) 37 38 
Women 57 (16.6) 61 (17.5) 
Race   
American Indian or Alaska Native 1 (0.3%) 2 (0.6%) 
Asian 44 (12.8%) 37 (10.6%) 
Black or African Heritage 65 (18.9%) 63 ( 18.1%) 
Native Hawaiian or Pacific Islander 1 (0.3%) 1 (0.3%) 
White 198 (57.6%) 215 (61.8%) 
Other 33 (9.6%) 27 (7.8%) 
Unknown 2 (0.6%) 3 (0.9%) 
Ethnicity Origin   
Hispanic/Latino 98 (28.5%) 92 (26.4%) 
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Body mass index (kg/m2), mean (SD) 25.2 (4.54) 25.0 (4.70) 
Positive HBV surface antigen 16 (4.7) 9 (2.6) 
Positive HCV antibody 21 (6.1) 16 (4.6) 
HIV-1 RNA (log10 c/mL), median 4.78 4.84 
>100,000 c/mL 132 (38.4) 143 (41.1) 
CD4 count (cells/mm3), mean (SD) 353 (170.5) 351 (175.5) 
≤200 60 (17.4) 57 (16.4) 
201 to ≤350 114 (33.1) 126 (36.2) 
351 to ≤500 123 (35.8) 117 (33.6) 
> 500 47 (13.7) 48 (13.8) 
Data are no. (%) unless otherwise indicated.  
Abbreviations: ATV, atazanavir; COBI, cobicistat; RTV, ritonavir; HBV, hepatitis B virus; HCV, hepatitis C virus. 
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Table 2. Virologic outcome (HIV-1 RNA Cutoff at 50 copies/mL) at Week 48 using FDA Snapshot Analysis (ITT Analysis Set) 
 
 
COBI  
(n=344) 
RTV  
(n=348) 
293 (85.2) 304 (87.4) 
Virologic success Difference: -2.2% (95% CI: -7.4 to 3.0%)a 
(P=0.40) 
Virologic failure 20 (5.8) 14 (4.0) 
  HIV-1 RNA ≥50 copies/mL 6 (1.7) 7 (2.0) 
  DC study drug due to lack of efficacy 1 (0.3) 0 
  DC study drug due to other reasonsb and last HIV-1 RNA ≥50 copies/mL  13 (3.8) 7 (2.0) 
No virologic data at Week 48 window 31 (9.0) 30 (8.6) 
  DC study drug due to adverse events or death 22 (6.4) 23 (6.6) 
  DC study drug due to other reasonsb and last HIV-1 RNA <50 copies/mL   9 (2.6) 7 (2.0) 
  Missing data during window but on study 0 0 
Data are no. (%) unless otherwise indicated.  
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Abbreviations: ATV, atazanavir; COBI, cobicistat; RTV, ritonavir; ITT, intent to treat; DC, discontinuation; CI, confidence interval. 
a Difference in percentages of virologic success and its 95.2% CI were calculated based on baseline HIV-1 RNA stratum-adjusted Mantel-Haenszel proportion. 
b Discontinuation due to other reasons includes patients who discontinued study drug due to investigator's discretion, withdrew consent, lost to follow-up, patient 
noncompliance, protocol violation, and pregnancy. 
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 Table 3. Common adverse events occurring in at least 10% of patients in either group 
 
COBI  
(n=344) 
RTV  
(n=348) 
P value 
Jaundice 72 (20.9) 54 (15.5) 0.076 
Sclearal icterus 61 (17.7) 64 (18.4) 0.84 
Nausea 61 (17.7) 57 (16.4) 0.69 
Diarrhea 53 (15.4) 71 (20.4) 0.093 
Headache 38 (11.0) 54 (15.5) 0.093 
Nasopharyngitis 37 (10.8) 53 (15.2) 0.09 
Hyperbilirubinemia 39 (11.3) 34 (9.8) 0.54 
Upper respiratory infection 35 (10.2) 28 (8.0) 0.36 
Data are no. (%) unless otherwise indicated.  
Abbreviations: ATV, atazanavir; COBI, cobicistat; RTV, ritonavir 
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Table 4. Adverse events leading to discontinuation of study drug in more than one patient in either group 
 
COBI  
(n=344) 
RTV  
(n=348) 
Scleral Icterus 8 (2.3%) 4 (1.1%) 
Jaundice 9 (2.6%) 7 (2.0%) 
Hyperbilirubinaemia 1 (0.3%) 2 (0.6%) 
Rash 1 (0.3%) 2 (0.6%) 
Dermatitis Allergic 2 (0.6%) 0 
Data are no. (%) unless otherwise indicated.  
Abbreviations: ATV, atazanavir; COBI, cobicistat; RTV, ritonavir
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Figure Legend 
Figure 1. Patient disposition Through Week 48 
Abbreviations: ATV, atazanavir; co, COBI; r, RTV; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate 
 
Figure 2. Patients with HIV-1 RNA < 50 copies/mL (ITT, missing = failure) 
Abbreviations: ATV, atazanavir; COBI, cobicistat; RTV, ritonavir; ITT, intent to treat; M=F, missing=failure 
 
Figure 3. Median change from baseline in serum creatinine (mg/dL) and estimated glomerular filtration rate (Whiskers indicate 1st and 
3rd quartiles) 
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Figure 1 
Randomized and Treated 
(N=692) 
COBI 
Randomized and Treated 
(n=344) 
RTV 
Randomized and Treated 
(n=348) 
11% Discontinued 
(n=39) 
89% Continued 
(n=309) 
25 Adverse event 25 
11 Lost to follow-up 4 
4 Patient non-compliance 3 
4 Withdrew consent 2 
3 Investigator discretion 1 
2 Lack of efficacy 0 
1 Pregnancy 3 
0 Protocol violation 1 
0 Death 0 
85% Continued 
(n=294) 
15% Discontinued 
 (n=50) 
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